Compare
Neumora Therapeutics, Inc. vs Editas Medicine, Inc. vs Agenus Inc vs TScan Therapeutics, Inc.
| Latest fiscal year | Neumora Therapeutics, Inc. NMRA | Editas Medicine, Inc. EDIT | Agenus Inc AGEN | TScan Therapeutics, Inc. TCRX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | n/a | $40.52M | $114.20M | $10.32M |
| Revenue growth (YoY) | n/a | +25.4% | +10.4% | +266.7% |
| Gross margin | n/a | n/a | n/a | n/a |
| Operating margin | n/a | -394.9% | -17.7% | n/m |
| Net margin | n/a | -395.0% | -2.7% | n/m |
| Net income | -$236.93M | -$160.06M | -$3.08M | -$129.77M |
| EPS (Diluted) | -$1.45 | -$1.80 | $0.00 | -$1.00 |
| Operating cash flow | -$206.44M | -$165.24M | -$77.19M | -$135.32M |
| Free cash flow | n/a | -$165.85M | -$77.20M | -$139.73M |
| Cash & equivalents | $182.53M | $146.65M | $3.00M | $152.41M |
| Total assets | $191.05M | $186.53M | $226.80M | $228.79M |
| Total liabilities | $87.18M | $159.25M | n/a | $105.67M |
| Shareholders' equity | $103.87M | $27.29M | -$271.11M | $123.12M |
| Return on year-end equity | -228.1% | -586.6% | n/a | -105.4% |
| Shares outstanding | 174.26M | 97.87M | 35.32M | n/a |
Revenue, most recent five fiscal years
| Fiscal year | Neumora Therapeutics, Inc. | Editas Medicine, Inc. | Agenus Inc | TScan Therapeutics, Inc. |
|---|---|---|---|---|
| Latest | n/a | $40.52M Ended 2025-12-31 | $114.20M Ended 2025-12-31 | $10.32M Ended 2025-12-31 |
| 1 year earlier | n/a | $32.31M Ended 2024-12-31 | $103.46M Ended 2024-12-31 | $2.82M Ended 2024-12-31 |
| 2 years earlier | n/a | $78.12M Ended 2023-12-31 | $156.31M Ended 2023-12-31 | $21.05M Ended 2023-12-31 |
| 3 years earlier | n/a | $19.71M Ended 2022-12-31 | $98.02M Ended 2022-12-31 | $13.54M Ended 2022-12-31 |
| 4 years earlier | n/a | $25.54M Ended 2021-12-31 | $295.67M Ended 2021-12-31 | $10.14M Ended 2021-12-31 |